IC
BEAM icon

Innealta Capital’s Beam Therapeutics BEAM Stock Holding History

Innealta Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-239
Closed -$5.6K – 325
2024
Q2 		$5.6K Buy
+239
New +$5.87K ﹤0.01% 908

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Innealta Capital's BEAM Position: Q3 2024 in Review

Innealta Capital sold out of Beam Therapeutics (BEAM) in Q3 2024, closing a stake of 239 shares — an estimated $5.6K sold.

Innealta Capital first reported a position in BEAM in Q2 2024 and held it in 1 quarter. The position peaked at $5.6K in Q2 2024. 221 funds tracked by Wall St. Rank hold BEAM as of Q3 2024.

  • Innealta Capital reported no remaining Beam Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 239 Beam Therapeutics shares in Q3 2024, an estimated $5.6K.
  • Innealta Capital first reported a position in Beam Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Beam Therapeutics position peaked at $5.6K in Q2 2024.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.